CELU logo

Celularity (CELU) Company Overview

Profile

Full Name:

Celularity Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

August 8, 2019

Indexes:

Not included

Description:

Celularity is a biotechnology company focused on developing innovative cell therapies. They use placental cells to create treatments for various diseases, including cancer and immune disorders. Their goal is to harness the power of the immune system to improve patient health and outcomes.

Key Details

Price

$1.40

Annual Revenue

$22.77 M(+26.68% YoY)

Annual EPS

-$110.20(-11700.00% YoY)

Annual ROE

-163.67%

Beta

2.18

Events Calendar

Earnings

Next earnings date:

Oct 16, 2025

Recent quarterly earnings:

Jan 10, 2025

Recent annual earnings:

Mar 31, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 29, 2024

Analyst ratings

Recent major analysts updates

Jan 30, 23 Morgan Stanley
Underweight
Jan 30, 23 HC Wainwright & Co.
Buy
Dec 22, 22 Oppenheimer
Perform
Sep 12, 22 Morgan Stanley
Equal-Weight
Aug 25, 22 Alliance Global Partners
Buy
Aug 23, 22 Truist Securities
Hold
Jun 22, 22 HC Wainwright & Co.
Buy
Apr 6, 22 Truist Securities
Hold
Jan 28, 22 Oppenheimer
Outperform
Nov 24, 21 Morgan Stanley
Equal-Weight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Celularity?
  • Does Celularity pay dividends?
  • What sector is Celularity in?
  • What industry is Celularity in?
  • What country is Celularity based in?
  • When did Celularity go public?
  • Is Celularity in the S&P 500?
  • Is Celularity in the NASDAQ 100?
  • Is Celularity in the Dow Jones?
  • When was Celularity's last earnings report?
  • When does Celularity report earnings?
  • Should I buy Celularity stock now?

What is the ticker symbol for Celularity?

The ticker symbol for Celularity is NASDAQ:CELU

Does Celularity pay dividends?

No, Celularity does not pay dividends

What sector is Celularity in?

Celularity is in the Healthcare sector

What industry is Celularity in?

Celularity is in the Biotechnology industry

What country is Celularity based in?

Celularity is headquartered in United States

When did Celularity go public?

Celularity's initial public offering (IPO) was on August 8, 2019

Is Celularity in the S&P 500?

No, Celularity is not included in the S&P 500 index

Is Celularity in the NASDAQ 100?

No, Celularity is not included in the NASDAQ 100 index

Is Celularity in the Dow Jones?

No, Celularity is not included in the Dow Jones index

When was Celularity's last earnings report?

Celularity's most recent earnings report was on Jan 10, 2025

When does Celularity report earnings?

The next expected earnings date for Celularity is Oct 16, 2025

Should I buy Celularity stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions